Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $22.45, for a total value of $4,490,000.00. Following the transaction, the chief executive officer owned 1,611,749 shares of the company’s stock, valued at approximately $36,183,765.05. This trade represents a 11.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total value of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total value of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The stock was sold at an average price of $17.06, for a total value of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The shares were sold at an average price of $16.93, for a total transaction of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total transaction of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total transaction of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The stock was sold at an average price of $16.30, for a total value of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The shares were sold at an average price of $16.34, for a total value of $2,800,610.64.

Roivant Sciences Stock Performance

Shares of ROIV traded down $0.53 during mid-day trading on Monday, hitting $21.70. 5,266,402 shares of the stock were exchanged, compared to its average volume of 8,130,591. The company has a market cap of $15.09 billion, a PE ratio of -38.75 and a beta of 1.22. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $23.47. The firm has a 50-day moving average of $20.65 and a two-hundred day moving average of $15.59.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC boosted its stake in Roivant Sciences by 36.4% in the first quarter. HighTower Advisors LLC now owns 13,932 shares of the company’s stock valued at $141,000 after acquiring an additional 3,719 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after purchasing an additional 2,233 shares in the last quarter. Jump Financial LLC grew its stake in Roivant Sciences by 31.1% during the 1st quarter. Jump Financial LLC now owns 14,970 shares of the company’s stock worth $151,000 after buying an additional 3,553 shares during the last quarter. Quarry LP purchased a new position in Roivant Sciences during the 1st quarter worth $129,000. Finally, Caption Management LLC increased its position in Roivant Sciences by 70.7% during the 1st quarter. Caption Management LLC now owns 256,661 shares of the company’s stock valued at $2,590,000 after buying an additional 106,323 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent research reports. JPMorgan Chase & Co. upped their target price on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Leerink Partners lifted their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Finally, Jefferies Financial Group lifted their price target on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.